Sarcosine for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Sarcosine for Health & Longevity

Created on 08/14/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

Short add-on trials show possible gains in leftover schizophrenia symptoms, reduced motivation or flattened mood, and depressive scores; thinking-speed evidence is weaker and less consistent. Weeks-to-months psychiatric-trial safety has been favorable. Whether it can make prostate cells more invasive remains unresolved. Elevated mood and reduced sleep have been reported with antidepressants. Muscle-aging use is not a human treatment trial. (Full Review)

Protocol

Taiwan fixed-dose regimen (Tsai/Lane)
2 g by mouth once daily
Most schizophrenia trials; Examine 30 mg/kg (~2.0–2.7 g for 70–90 kg)
Flexible psychiatric titration
0.5–2 g/day
Often starting at 500 mg and rising as tolerated
Time of day
Morning or midday
Short half-life (~1 hour); case-level reduction in sleep need
Time to effect
Psychiatric rating-scale changes
2–6 weeks
Appeared in trials
Drive or mood shifts
1–2 weeks
Some open-label reports

Benefits

Contraindications
  • Active or recently treated prostate cancer, or a rising PSA without a completed work-up
  • Current mania or untreated bipolar I disorder
  • Known SARDH deficiency (sarcosinemia)
  • Pregnancy or lactation (no adequate human data)
    •
Key Interactions
  • Clozapine (Clozaril)
  • Serotonin-reuptake inhibitors (citalopram, escitalopram) and serotonin-norepinephrine reuptake inhibitors (venlafaxine)
  • Other NMDA facilitators (D-serine, glycine, sodium benzoate, D-cycloserine)
  • NMDA blockers (ketamine, esketamine, memantine, dextromethorphan)
  • Antipsychotics other than clozapine (risperidone, olanzapine, quetiapine)
  • One-carbon supplements (folate, cobalamin, choline, betaine, glycine)
    •

Risk & Side Effects

  • High:
  • Medium: Prostate Cancer Biology
    •
  • Low: Mood Elevation and Hypomania; Headache
    •
  • Speculative: NMDA Overactivation
    •

Monitoring

Marker Target Why
PSA (men) Prefer <1.0 ng/mL if previously low; investigate any clear rise from personal baseline Flags prostate tissue activity
Homocysteine 6–8 µmol/L Reads the one-carbon / methylation pool
Folate (serum or RBC) Serum >15 ng/mL or red-cell folate in the upper laboratory third Cofactor for the one-carbon unit
Cobalamin (vitamin B12) >500 pg/mL Partner of folate in methyl-group recycling
Plasma glycine No established supplement target; track change from personal baseline Sarcosine is both a glycine product and a glycine precursor
Plasma sarcosine (if available) No established target Documents exposure and the aging-metabolite signal

Cadence: Two-week mood, sleep, and attention log at start; laboratories at baseline, 4–8 weeks, then every 6–12 months if use continues

Qualitative Assessment

  • Sleep duration and sleep need versus the two-week baseline
  • Mood stability, irritability, and any reduced need for sleep
  • Cognitive clarity, working memory, and processing speed on a repeated task
  • Drive and inner tension (early activation clues)
  • Training recovery and subjective muscle function in older users
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.